Nxtm, Enz, Valu, Avot, Mnta - Stock Report From Drstockpick.com!

Dec. 22, 2010 - PRLog -- American Video Teleconferencing Corp. (Pink Sheets:AVOT) is pleased to announce that it is presently in final discussions to enter into a formal agreement to acquire an exclusive option on a molybdenum property in the Otter lake area in the province of Quebec, Canada. The property has been dormant since the 1960's when Hupon Mining and Exploration carried out surface work, stripping, trenching and a minor drill program of 445 feet contained in 11 drill holes. Some of the sample results from the trenching in 1962 showed 0.94% to 25% molybdenum averaging 5-10%. These values were obtained from assessment files in the Department of Mines in Quebec City.

This property is only one of several advanced stage properties the company has under consideration in the province of Quebec.

Rare earth elements have become irreplaceable in clean tech such as hybrid and electric car motors, high-efficiency light bulbs, solar panels and wind turbines. They also play a key role in defense technologies such as cruise missiles, radar and sonar and precision-guided weapons.

Experts warn that the U.S. depends upon China for almost its entire supply of rare earths, and has let its own rare earth production languish despite having about 15 percent of the world's reserves. A draft of a Chinese rare earths plan for 2009-2015 states that China's own industrial demand could soon lead to restrictions or bans on the export of rare earths.

The U.S. Geological Survey (USGS) has noted that 91 percent of U.S. consumption of rare earths came from China between 2005 and 2008.

China is the world's largest producer of rare earth elements, most of which are used in modern technology, such as new energy sources and hybrid cars. It announced in July that it will cut exports for minerals used to make hybrid cars and televisions by 72 percent in the second half of the year.

China has started to severely restrict the exports of rare-earth materials, which often find use in “green” technology designs, including hybrid vehicles and energy-efficient lighting, as well as in the medical, defense, and consumer markets. The country delivers nearly 100% of the world’s rare-earth materials: 17 metals that are somewhat hard to refine and that tend to occur in the same ore deposits.

***********************************************



Enzo Biochem, Inc.  reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”

“Moreover, in the first quarter, we achieved several milestones. We submitted Colon Sentry, a unique assay for risk-stratification of colon cancer occurrence, to the New York State Department of Health for approval. In addition, we began enrolling the first patients in our clinical trial of Optiquel™, our candidate therapeutic for the treatment of autoimmune uveitis.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Eastern Pennsylvania and New Jersey.

***********************************************

Momenta Pharmaceuticals Inc  announced that it has completed the underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $14.35 per share. The net proceeds to Momenta from the sale of shares in this offering, after deducting customary underwriting discounts and commissions, were approximately $54.2 million.

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules.

***********************************************

Value Line, Inc.  reported results for its fiscal quarter ended October 31, 2010. For the six months ended October 31, 2010, the Company’s net income of $3,404,000 or $0.34 per share compared to the net loss of $29,199,000 or $2.93 per share for the six months ended October 31, 2009. Net income for the second quarter ended October 31, 2010 of $1,087,000 or $0.11 per share was $1,294,000 or 54% below net income of $2,381,000 or $0.23 per share for the second quarter of the prior fiscal year.

Value Line, Inc. principally engages in the production of investment related periodical publications and provision of investment management services primarily in the United States.

***********************************************

Nxstage Medical, Inc.  a leading manufacturer of innovative dialysis products, announced on December 16, 2010 that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System One™, the only hemodialysis machine cleared by the FDA for home use.

NxStage Medical, Inc., a medical device company, engages in the development, manufacture, and marketing of products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures in the United States.

***************************************************************************





THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (AVOT.PK) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.